ليست عنوان مقالات لاتين Pharmacokinetic Investigation to Study the In Vivo Bioavailability of Thiolated Chitosan Based Repaglinide Buccal Tablets Phase Calibration Technique for Mismatch Optimization in Image-Reject Receivers

<< مقالات لاتين >>

<< بر اساس عنوان >>

1

Pharmacokinetic Investigation to Study the In Vivo Bioavailability of Thiolated Chitosan Based Repaglinide Buccal Tablets

2

Pharmacokinetic model for in vivo/in vitro correlation of intravitreal drug delivery

3

Pharmacokinetic model of daily selenium intake from contaminated seafood in Taiwan

4

Pharmacokinetic model of dioxin and furan levels in adipose tissue from Sawmill work involving chlorophenate fungicides

5

Pharmacokinetic of ALA and h-ALA induced porphyrins in the models Mycobacterium phlei and Mycobacterium smegmatis

6

Pharmacokinetic of sulfaclozine in broiler chickens

7

Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. implementation of P3 pyridine N-Oxides to deliver an orally bioavailable series containing P1 N-Benzylamides

8

Pharmacokinetic Parameters and OverResponsiveness of Iranian Population to Propranolol

9

Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol

10

Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI

11

Pharmacokinetic parameters of valproic acid and carbamazepine from routinely collected data: Influence of patient characteristics

12

Pharmacokinetic profile of a sustained-delivery system for physostigmine in rats

13

Pharmacokinetic Profile of Controlled-Release Carvedilol in Patients with Left Ventricular Dysfunction Associated with Chronic Heart Failure or After Myocardial Infarction

14

Pharmacokinetic Profile of Plasma Levobupivacaine Following Fascia Iliaca Compartment Block for Proximal Femoral Fracture in Older Patient

15

Pharmacokinetic profile of recombination human insulin-like growth factor binding protein-1 in athymic mice

16

Pharmacokinetic Properties of a New Controlled-Release Formulation of Carvedilol

17

Pharmacokinetic studies and human absorbed dose estimation of 68Ga-(4 {[(bis (phosphonomethyl)) carbamoyl] methyl}-7,10-bis(carboxymethy l) -1,4,7,10-tetraazacyclododec-1-yl) acetic acid

18

Pharmacokinetic studies in cancer chemotherapy: Usefulness in clinical practice

19

Pharmacokinetic Studies of Enrofloxacin in Yak after Intramuscular Administration

20

Pharmacokinetic studies of metformin and glibenclamide in normal human volunteers

21

Pharmacokinetic studies of protein drugs: Past, present and future

22

Pharmacokinetic Studies of Rifampicin in Healthy Volunteers and Tuberculosis Patients

23

Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues

24

Pharmacokinetic Studies on Metoprolol - Eudragit Matrix Tablets and Bioequivalence Consideration with Mepressor®

25

Pharmacokinetic Studies on Oximes in Organophosphate Poisoning: A Mini Review

26

Pharmacokinetic Study of a Capsule-based Chronomodulated Drug Delivery System of Salbutamol Sulphate in Rabbits

27

Pharmacokinetic study of acyl-protected hydroxylamine probe, 1-acetoxy-3-carbamoyl-2,2,5,5-tetramethylpyrrolidine, for in vivo measurements of reactive oxygen species

28

Pharmacokinetic study of calenduloside E and its active metabolite oleanolic acid in beagle dog using liquid chromatography–tandem mass spectrometry

29

Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment

30

PHARMACOKINETIC STUDY OF CEPHRADINE IN PAKISTANI HEALTHY MALE VOLUNTEERS

31

Pharmacokinetic study of dicloxacillin sodium following intravenous and intramuscular administration to pigs

32

Pharmacokinetic study of dl-tetrahydropalmatine patches by UPLC–MS/MS in rabbits

33

Pharmacokinetic study of ellagic acid in rat after oral administration of pomegranate leaf extract

34

Pharmacokinetic study of free mangiferin in rats by microdialysis coupled with microbore high-performance liquid chromatography and tandem mass spectrometry

35

Pharmacokinetic study of furosemide incorporated PLGA microspheres after oral administration to rat

36

Pharmacokinetic study of HS061, a new human insulin, in non-diabetic rat using ultra performance liquid chromatography–tandem mass spectrometry

37

Pharmacokinetic study of levofloxacin in rat blood and bile by microdialysis and high-performance liquid chromatography

38

Pharmacokinetic study of mangiferin in human plasma after oral administration

39

Pharmacokinetic study of melamine in rhesus monkey after a single oral administration of a tolerable daily intake dose

40

Pharmacokinetic study of multiple active constituents from Kushen–Gancao Decoction after oral administration in rat by HPLC–MS/MS

41

Pharmacokinetic study of mycophenolic acid in Iranian kidney transplant patients.

42

Pharmacokinetic Study of Nifedipine in Healthy Adult Male Human Volunteers

43

Pharmacokinetic study of niosome-loaded insulin in diabetic rats

44

Pharmacokinetic study of orphenadrine using high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS)

45

Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride

46

Pharmacokinetic variability of extended interval tobramycin in burn patients

47

PHARMACOKINETIC VARIATIONS OF OFLOXACIN IN NORMAL AND FEBRILE RABBITS

48

Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies

49

Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients

50

Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes

51

Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology

52

Pharmacokinetic-pharmacodynamic indices of enrofloxacin in Escherichia coli O78/H12 infected chickens

53

Pharmacokinetic-Pharmacodynamic Modeling: Why?

54

Pharmacokinetic–pharmacodynamic models for categorical toxicity data

55

Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep

56

Pharmacokinetics after pulmonary artery perfusion with gemcitabine

57

Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill Patients

58

Pharmacokinetics and Bioavailability Comparison of two oral Tablet Formulations of Escitalopram 20 mg: A Single-Dose, Open-Label, Two-Period Crossover Study in Healthy Indian Adult Subjects

59

Pharmacokinetics and bioavailability of diisopropanolamine (DIPA) in rats following intravenous or dermal application

60

Pharmacokinetics and bioavailability study of polydatin in rat plasma by using a LC–MS/MS method

61

Pharmacokinetics and Biodistribution of Pegylated Methotrexate after IV Administration to Mice

62

Pharmacokinetics and Biodistribution of Rhopalurus junceus Scorpion Venom in Tumor-Bearing Mice after Intravenous and Oral Administration

63

Pharmacokinetics and Bioequivalence of Methotrexate in Human Plasma Studied by Liquid Chromatography-Mass Spectrometry (LC-MS)

64

Pharmacokinetics and Bioequivalence Study of Two Formulations of Cefixime in Healthy Male Volunteers

65

Pharmacokinetics and brain distribution of unbound levamisole in the anesthetized rats using microdialysis and microbore column liquid chromatography Original Research Article

66

Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant

67

Pharmacokinetics and Dosage Regimen of Cefepime following Single Dose Intravenous Administration in Calves

68

Pharmacokinetics and Dosage Regimen of Cefpirome in Febrile Cross-Bred Calves

69

PHARMACOKINETICS AND DOSAGE REGIMEN OF CIPROFLOXACIN FOLLOWING SINGLE INTRAMUSCULAR ADMINISTRATION IN TEDDY GOATS

70

Pharmacokinetics and dosimetry of 188Re-pharmaceuticals

71

Pharmacokinetics and Effects of Alkalization after Intravenous Administration of Eltenac in Horses

72

Pharmacokinetics and Effects of Alkalization During Oral and Intravenous Administration of Naproxen in Horses

73

Pharmacokinetics and effects of cetirizine in horses with insect bite hypersensitivity

74

Pharmacokinetics and efficacy of intravenous and extradural tramadol in dogs

75

Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease

76

Pharmacokinetics and ex vivo pharmacodynamics of cefquinome in porcine serum and tissue cage fluids

77

Pharmacokinetics and excretion study of sophoricoside and its metabolite in rats by liquid chromatography tandem mass spectrometry

78

Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure

79

Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver

80

Pharmacokinetics and in vivo chemosuppressive activity studies on cryptolepine hydrochloride and cryptolepine hydrochloride-loaded gelatine nanoformulation designed for parenteral administration for the treatment of malaria

81

Pharmacokinetics and interaction pharmacodynamics of dexmedetomidine in humans

82

Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius)

83

Pharmacokinetics and metabolic effects of triamcinolone acetonide and their possible relationships to glucocorticoid-induced laminitis in horses

84

Pharmacokinetics and metabolism of 3,4-dichlorophenyl-propenoyl-sec.-butylamine in rats by high performance liquid chromatography–ion trap mass spectrometry

85

Pharmacokinetics and metabolism of single oral doses of trovafloxacin

86

Pharmacokinetics and metabolism studies on (3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy) pyrazolo[1,5-d][1,2,4]triazine, a functionally selective GABAA α5 inverse agonist for cognitive dysfunction

87

Pharmacokinetics and metabolite identification of a novel VEGFR-2 and Src dual inhibitor 6-chloro-2-methoxy-N-(2-methoxybenzyl) acridin-9-amine in rats by liquid chromatography tandem mass spectrometry

88

Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats

89

Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats

90

Pharmacokinetics and Molecular Docking Studies of Uridine Derivatives as SARSCOV-2 Mpro Inhibitors

91

Pharmacokinetics and Pharmacodynamic Effects of Flunixin after Intravenous, Intramuscular and Oral Administration to Dairy Goats

92

Pharmacokinetics and pharmacodynamic effects of tolazoline following intravenous administration to horses

93

Pharmacokinetics and pharmacodynamics of d-chlorpheniramine following intravenous and oral administration in healthy Thoroughbred horses

94

Pharmacokinetics and Pharmacodynamics of Gliclazide from Immediate and Modified Release Formulation Tablets in Rats

95

Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors

96

Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy

97

Pharmacokinetics and pharmacodynamics of tetra(m-hydroxyphenyl)chlorin in the hamster cheek pouch tumor model: comparison with clinical measurements

98

Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites

99

Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy

100

Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy

101

Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy

102

Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids

103

Pharmacokinetics and radiation dosimetry estimation of O-(2-[18F]fluoroethyl)-image-tyrosine as oncologic PET tracer

104

Pharmacokinetics and residual behaviour in milk of oxytetracycline in cows following administration of uterine pessaries

105

Pharmacokinetics and residues of a new oral amoxicillin formulation in piglets: A preliminary study

106

Pharmacokinetics and residues of tetracycline in crucian carp muscle using capillary electrophoresis on-line coupled with electrochemiluminescence detection

107

Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass

108

Pharmacokinetics and tissue and milk disposition of Tilmicosin in sheep after single administrations

109

Pharmacokinetics and tissue distribution of a novel marine fibrinolytic compound in Wistar rat following intravenous administrations

110

Pharmacokinetics and Tissue Distribution of Antimony(v) after Multiple Intramuscular Administrations in the Hamster

111

Pharmacokinetics and tissue distribution of bovine testicular hyaluronidase and vinblastine in mice: an attempt to optimize the mode of adjuvant hyaluronidase administration in cancer chemotherapy

112

Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography–mass spectrometry: Evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier

113

Pharmacokinetics and tissue distribution of the antileukaemic organoarsenicals arsthinol and melarsoprol in mice

114

Pharmacokinetics and Tolerability of Iopromide 240 After Lumbar Myelography

115

Pharmacokinetics in gene delivery

116

Pharmacokinetics in pregnancy

117

Pharmacokinetics in the elderly

118

Pharmacokinetics in the newborn

119

Pharmacokinetics of a long-acting oxytetracycline-polyethylene glycol formulation in horses

120

Pharmacokinetics of a Mono-pyridinium-mono-aldoxime (K-347), a Potential Antidote in Organophosphate Poisoning

121

Pharmacokinetics of a tri-glucoconjugated 5,10,15-(meta)-trihydroxyphenyl-20-phenyl porphyrin photosensitizer for PDT. A single dose study in the rat

122

Pharmacokinetics of albendazole sulfoxide enantiomers administered in racemic form and separately in rats

123

Pharmacokinetics of alprazolam in elderly patients with multiple diseases

124

Pharmacokinetics of aminomethylpropanol in rats following oral and a novel dermal study design

125

Pharmacokinetics of Amoxicillin/Clavulanic Acid Combination after Oral Administration of New Suspension Formulations in Human Volunteers

126

Pharmacokinetics of an ampicillin–sulbactam combination after intravenous and intramuscular administration to neonatal calves

127

Pharmacokinetics of anticancer drugs, plasmid DNA, and their delivery systems in tissue-isolated perfused tumors

128

Pharmacokinetics of betamethasone after maternal or fetal intramuscular administration

129

Pharmacokinetics of buprenorphine after intravenous administration of clinical doses to dogs

130

PHARMACOKINETICS OF CALCIUM FROM CALCIUM SUPPLEMENTS IN HEALTHY VOLUNTEERS

131

Pharmacokinetics of calycopterin and xanthmicrol, two polymethoxylated hydroxyflavones with anti-angiogenic activities from Dracocephalum kotschyi Bioss

132

Pharmacokinetics of Cefepime Following Intravenous and Intramuscular Administration in Sheep

133

Pharmacokinetics of ceftazidime after intravenous and intramuscular administration to domestic cats

134

Pharmacokinetics of ceftazidime in buffalo calves following intravenous and intramuscular administration

135

Pharmacokinetics of ceftiofur sodium in equine pregnancy

136

Pharmacokinetics of ceftriaxone in buffalo calves (Bubalus bubalis) following intravenous and intramuscular administration

137

Pharmacokinetics of Cephalexin in the Horse After Intravenous and Intramuscular Administration of Two Formulations

138

Pharmacokinetics of ciprofloxacin in bath medicated hybrid tilapias using enzyme linked immunosorbent assay (ELISA)

139

PHARMACOKINETICS OF CIPROFLOXACIN IN NORMAL RABBITS AND CHANGES OBSERVED IN INDUCED DEHYDRATED STATE

140

Pharmacokinetics of ciprofloxacin in sheep following intravenous and subcutaneous administration

141

Pharmacokinetics of ciprofloxacin in the rat and its interaction with cyclosporin A: a microdialysis study Original Research Article

142

Pharmacokinetics of Clozapine: An Investigate the Potential Molecular Mechanisms of Action

143

Pharmacokinetics of combined doxorubicin and paclitaxel in mice

144

Pharmacokinetics of conjugated metabolites in rat plasma after oral administration of tectoridin

145

Pharmacokinetics of curcumin-loaded PLGA and PLGA–PEG blend nanoparticles after oral administration in rats

146

Pharmacokinetics of dexamethasone after intravenous and intramuscular administration in broiler chickens

147

Pharmacokinetics of dexamethasone after intravenous and intramuscular administration in pigs

148

Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects

149

Pharmacokinetics of Dextran-70 in patients with cirrhosis and ascites undergoing therapeutic paracentesis

150

Pharmacokinetics of Diclofenac in Sheep Following Intravenous and Intramuscular Administration

151

Pharmacokinetics of Diclofenac in Sheep Following Intravenous and Intramuscular Administration

152

Pharmacokinetics of dl-praeruptorin A after single-dose intravenous administration to rats with liver cirrhosis

153

Pharmacokinetics of Doramectin and Ivermectin After Oral Administration in Horses*

154

Pharmacokinetics of doramectin in lactating dairy sheep and suckling lambs Original Research Article

155

Pharmacokinetics of doxycycline in sheep after intravenous and oral administration

156

Pharmacokinetics of enrofloxacin and flunixin meglumine and interactions between both drugs after intravenous co-administration in healthy and endotoxaemic rabbits

157

Pharmacokinetics of Enrofloxacin and Its Active Metabolite Ciprofloxacin and Its Interaction With Diclofenac After Intravenous Administration in Buffalo Calves

158

Pharmacokinetics of Enrofloxacin and its Metabolite Ciprofloxacin in Goats given Enrofloxacin Alone and in Combination with Probenecid

159

Pharmacokinetics of enrofloxacin and the rate of formation of its metabolite ciprofloxacin following intravenous and intramuscular single dose administration to male buffalo calves

160

Pharmacokinetics of ergosterol in rats using rapid resolution liquid chromatography–atmospheric pressure chemical ionization multi-stage tandem mass spectrometry and rapid resolution liquid chromatography/tandem mass spectrometry

161

Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats

162

Pharmacokinetics of exogenous gonadotropin and ovarian response in in vitro fertilization

163

Pharmacokinetics of fexofenadine in healthy Taiwanese volunteers

164

Pharmacokinetics of fleroxacin in horses

165

Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma

166

Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients

167

Pharmacokinetics of ganoderic acid D and its main metabolite by liquid chromatography–tandem mass spectrometry

168

Pharmacokinetics of Gefodizime in Patients with Various Degrees of Renal Failure

169

Pharmacokinetics of gentamicin in mares in late pregnancy and early lactation

170

Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs

171

Pharmacokinetics of HZ08 in rats by liquid chromatography–tandem mass spectrometry

172

Pharmacokinetics of ingested fluoride: Lack of effect of chemical compound

173

Pharmacokinetics of Intravascularly Administered 65Zinc in Channel Catfish (Ictalurus punctatus)

174

Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles

175

Pharmacokinetics of ionized versus total magnesium in subjects with preterm labor and preeclampsia

176

Pharmacokinetics of kadsurenone and its interaction with cyclosporin A in rats using a combined HPLC and microdialysis system

177

Pharmacokinetics of kakkalide and its main metabolites in rat plasma determined by HPLC-DAD and LC–MSn

178

Pharmacokinetics of ketoprofen enantiomers after intravenous administration of racemate in camels: effect of gender

179

Pharmacokinetics of L-arginine during chronic administration to patients with hypercholesterolaemia

180

Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression

181

Pharmacokinetics of lithium in rat brain regions by spectroscopic imaging

182

Pharmacokinetics of marbofloxacin after intravenous and intramuscular administration to ostriches

183

Pharmacokinetics of marbofloxacin after single intravenous and repeat oral administration to cats

184

Pharmacokinetics of melamine in pigs following intravenous administration

185

Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs

186

Pharmacokinetics of metronidazole in horses after intravenous, rectal and oral administration

187

Pharmacokinetics of metronidazole in rat blood, brain and bile studied by microdialysis coupled to microbore liquid chromatography

188

Pharmacokinetics of mirtazapine and its main metabolites after single intravenous and oral administrations in rats at two dose rates

189

Pharmacokinetics of Mirtazapine and Its Main Metabolites after Single Oral Administration in Fasting/Fed Horses

190

Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: A pilot study

191

Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves

192

Pharmacokinetics of oral gabapentin in greyhound dogs

193

Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy, , ,

194

Pharmacokinetics of pefloxacin mesylate in human urine using capillary electrophoresis electrochemiluminescence detection

195

Pharmacokinetics of Photogem using fluorescence monitoring in Wistar rats

196

Pharmacokinetics of piperine after oral administration of Sahastara remedy capsules in healthy volunteers

197

Pharmacokinetics of prostaglandins

198

Pharmacokinetics of protein-unbound linezolid in the blood and the mechanism of hepatobiliary excretion in the rat Original Research Article

199

Pharmacokinetics of protocatechuic acid in mouse and its quantification in human plasma using LC–tandem mass spectrometry

200

Pharmacokinetics of sodium and trihydrate amoxicillin after intravenous and intramuscular administration in llamas (Lama glama)

201

Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice

202

Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice

203

Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies

204

Pharmacokinetics of Sulpiride After Intravenous, Intramuscular, and Oral Single-Dose Administration in Nurse Mares

205

Pharmacokinetics of Tetracycline and Tetracycline Loaded Nanoemulsion Formula in Rabbits

206

Pharmacokinetics of tetracycline hydrochloride in fat-tailed sheep

207

Pharmacokinetics of the low molecular weight heparin dalteparin in cats

208

Pharmacokinetics of the novel atypical opioid tapentadol after intravenous, intramuscular and subcutaneous administration in cats

209

Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs

210

Pharmacokinetics of the potent redox-modulating manganese porphyrin, MnTE-2-PyP5+, in plasma and major organs of B6C3F1 mice

211

Pharmacokinetics of the Thymidine Analog 2-Fluoro-5[14C]-methy1-1-beta-D-arabinofuranosyluracil ([14C]FMAU) in Rat Prostate Tumor Cells

212

Pharmacokinetics of tobramycin in ducks and sex-related differences

213

Pharmacokinetics of Tramadol after Epidural Administration in Horses

214

Pharmacokinetics of Tramadol and its Metabolites M1, M2 and M5 in Horses Following Intravenous, Immediate Release (Fasted/Fed) and Sustained Release Single Dose Administration

215

Pharmacokinetics of Tramadol and Its Metabolites M1, M2, and M5 in Donkeys after Intravenous and Oral Immediate Release Single-Dose Administration

216

Pharmacokinetics of tulathromycin in lactating goats

217

Pharmacokinetics of two different delivery regimens of doxorubicin in isolated hyperthermic limb perfusion

218

PHARMACOKINETICS OF UMF-078, A CANDIDATE ANTIFILARIAL DRUG, IN INFECTED DOGS

219

Pharmacokinetics of zonisamide in perinatal period

220

Pharmacokinetics Studies of some Diaryl Pyrimidinamine Derivatives as Anti-Cancer Agent: In-Silico Drug Design and Molecular Docking

221

Pharmacokinetics study of chitosan-coated liposomes containing sumatriptan in the treatment of migraine

222

Pharmacokinetics, bioavailability and tissue residues of [14C]isometamidium in non-infected and Trypanosoma congolense-infected Boran cattle

223

Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel

224

Pharmacokinetics, dosage regimen and in vitro plasma protein binding of intramuscular levofloxacin in buffalo calves

225

Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl

226

Pharmacokinetics, immunogenicity and anticancer efficiency of Aspergillus flavipes l-methioninase

227

Pharmacokinetics, pharmacodynamics and toxicity of a combination of metoprolol succinate and telmisartan in Wistar albino rats: Safety profiling

228

Pharmacokinetics, safety, and effects on exercise performance of l-arginine α-ketoglutarate in trained adult men

229

Pharmacokinetics, tissue distribution and excretion of a new photodynamic drug deuxemether

230

Pharmacokinetics, tissue distribution and excretion study of dictamnine, a major bioactive component from the root bark of Dictamnus dasycarpus Turcz. (Rutaceae)

231

Pharmacokinetics, urinary excretion and plasma protein binding of 2,3-butanedione monoxime in goats

232

Pharmacokinetics, urinary excretion and plasma protein binding of pralidoxime in goats

233

Pharmacokmetics and oral bioavailability of a doxycycline formulation (DOXYCYCLINE 75%) in nonfasted young pigs

234

Pharmacokmetics and oral bioavailability of a doxycycline formulation (DOXYCYCLINE 75%) in nonfasted young pigs

235

Pharmacoligical characterization of the iranian Cerastes cerastes gasperettii (Reptilia: Ophidia: Viperidae) venom

236

Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription

237

Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer

238

Pharmacologic agents for the treatment of acute bipolar mania

239

Pharmacologic alterations in human type I atrial flutter cycle length and monophasic action potential duration Evidence of fully excitable gap in the reentrant circuit

240

Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches

241

Pharmacologic and Therapeutic Differences Among Calcium Channel Antagonists: Profile of Mibefradil, a New Calcium Antagonist

242

Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease

243

Pharmacologic approaches to rhythm versus rate control in atrial fibrillation—where are we now?

244

Pharmacologic approaches to therapy for vasovagal syncope

245

Pharmacologic Characterization of Wool Dust Extract in Isolated Guinea Pig Trachea

246

Pharmacologic evidence for a parasympathetic role in seizure-induced neurocardiac regulatory abnormalities

247

Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL

248

Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure

249

Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage

250

Pharmacologic management of childhood hypertension: current status, future challenges

251

Pharmacologic Management of Overactive Bladder: Practical Options for the Primary Care Physician

252

Pharmacologic modulation of neutrophil functions

253

Pharmacologic modulation of the collateral vascular resistance in acute and chronic coronary occlusion assessed by intracoronary blood flow velocity analysis

254

Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: Impact on hemodynamic function and left ventricular performance

255

Pharmacologic myocardial regeneration

256

Pharmacologic Options for Aggressive Low-Density Lipoprotein Cholesterol Lowering: Benefits Versus Risks

257

Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes

258

Pharmacologic preconditioning of estrogen by activation of the myocardial adenosine triphosphate-sensitive potassium channel in patients undergoing coronary angioplasty

259

Pharmacologic preservation of the hemostatic system during cardiac surgery

260

Pharmacologic prevention of poterior capule opacification: in vitro effect of preervative-free lidocaine 1 % on len epithelial cell

261

Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals

262

Pharmacologic Prophylaxis and Treatment of Venous Thromboembolism after Knee Arthroplasty

263

Pharmacologic Relevance of K+Channel Remodeling in Atrial Fibrillation

264

Pharmacologic strategies for augmenting cognitive performance in schizophrenia

265

Pharmacologic Strategies for Prevention of Atrial Fibrillation After Open Heart Surgery

266

Pharmacologic stress echocardiography: can we forget “state-of-the-art” protocols?

267

Pharmacologic stress testing for coronary disease diagnosis: A meta-analysis

268

Pharmacologic stress-induced regional myocardial blood flow heterogeneity and left ventricular wall thickening abnormality: Comparison of intravenous adenosine with dipyridamole in a model of critical coronary stenosis, , ,

269

Pharmacologic support with high-energy phosphate preservation in the postischemic neonatal heart

270

Pharmacologic therapies after myocardial infarction

271

Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations

272

Pharmacologic treatment of atherosclerosis: beyond lipid-lowering therapy

273

Pharmacologic treatment of hypertension in the Department of Veterans Affairs during 1995 and 1996

274

Pharmacologic treatment of schizophrenia

275

Pharmacologic Treatment of Wet Type Age-related Macular Degeneration; Current and Evolving Therapies

276

Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma

277

Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation

278

Pharmacologic versus flow-mediated assessments of peripheral vascular endothelial vasodilatory function in humans

279

Pharmacologic Vitreolysis

280

Pharmacological Action of Mentha piperita on Lipid Profile in Fructose-Fed Rats

281

Pharmacological action of tick saliva upon haemostasis and the neutralization ability of sera from repeated infested hosts

282

Pharmacological Activities of Hypnea musciformis

283

Pharmacological activity of 2% aqueous acetic acid extract of Alhagi maurorum roots

284

Pharmacological algorithms for treatment resistant depression in children and adolescents

285

Pharmacological analysis of ovarial patency in Heliothis virescens

286

Pharmacological and Antioxidant Activities of Rhus coriaria L. (Sumac)

287

Pharmacological and biochemical effects of Ginkgo biloba extract on learning, memory consolidation and motor activity in old rats

288

Pharmacological and biological evaluation of extracts from Gratiola officinalis L. (Scrophulariaceae)

289

Pharmacological and cognitive-behavioral approaches in the treatment of childhood depression: A review and critique

290

Pharmacological and computational evaluation of Sapodilla and its constituents for therapeutic potential in hyperactive gastrointestinal disorders

291

Pharmacological and Medical Effect of Modified Skin Grafting Method in Patients with Chronic and Severe Neck Burns

292

Pharmacological and Medicinal Aspects of the Verses Containing Fig (At-tin) in Holy Quran

293

Pharmacological and Medicinal Aspects of the Verses Containing Fig (At-tin) in Holy Quran

294

Pharmacological and molecular biological evidence for ETA endothelin receptor subtype mediating mechanical responses in the detrusor smooth muscle of the human urinary bladder

295

Pharmacological and Molecular Evidence of Neuroprotective Curcumin Effects Against Biochemical and Behavioral Sequels Caused by Methamphetamine: Possible Function of CREB-BDNF Signaling Pathway

296

Pharmacological and non- pharmacological treatment of hypertension: A review article

297

Pharmacological and non-pharmacological means for prevention of fractures among elderly

298

Pharmacological and Nonpharmacological Prevention of Atrial Fibrillation after Coronary Artery Bypass Surgery

299

Pharmacological and Nonpharmacological Studies on Coronavirus Disease 2019: A Mini‑review of the Recent Evidence

300

Pharmacological and Non-pharmacological Therapeutic Strategies for Improvement of State-Trait Anxiety: A Randomized Controlled Trial Among Iranian Infertile Women With Sexual Dysfunctions

301

Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibitors for the practising physician

302

Pharmacological and pharmacokinetic characterization of 2-piperazine-α-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists Original Research Article

303

Pharmacological and Radiological Study of Patients with COVID-19 in Iran

304

Pharmacological and surgical treatments for obesity

305

Pharmacological and toxicity effects of Zhumeria majdae and its bioactive constituents: A review

306

Pharmacological and toxicity studies of the crude extracts and fractions of Hedranthera barteri leaf in rats and mice

307

Pharmacological and toxicological insights to the South African Amaryllidaceae

308

Pharmacological application of caffeine inhibits TGF-β-stimulated connective tissue growth factor expression in hepatocytes via PPARγ and SMAD2/3-dependent pathways

309

Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article

310

Pharmacological Approach for Prevention of Bleomycin-Induced Lung Injury

311

Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis

312

Pharmacological approaches to discovery and development of new mucolytic agents

313

Pharmacological Aspects of Phyllanthus fraternus Standardized Extract (Rich in Lignans and Tannins) as a Pain Modulator

314

Pharmacological blockade of gap junctions induces repetitive surging of extracellular potassium within the locust CNS

315

Pharmacological chaperones and lysosomal storage diseases

316

Pharmacological characterisation of 5-hydroxytryptamine-induced contractile effects in the isolated gut of the lepidopteran caterpillar Spodoptera frugiperda

317

Pharmacological characterisation of extraneuronal transmitter store in porcine and human coronary arteries

318

Pharmacological Characterization of A2-Adenosine Receptors in Guinea-pig Ventricular Cardiomyocytes

319

Pharmacological Characterization of Effects of UK-1745, a Novel Cardiotonic Agent withβ-Adrenoceptor-blocking Action, in Aequorin-loaded Canine Right Ventricular Muscle

320

Pharmacological characterization of liquiritigenin, a chiral flavonoid in licorice

321

Pharmacological characterization of micropatterned cardiac myocytes

322

Pharmacological characterization of new β-agonists using Huβ1- and Huβ2-adrenergic receptor binding assay in transfected HEK-293 cells Original Research Article

323

Pharmacological characterization, localization, and regulation of ionotropic glutamate receptors in skate horizontal cells

324

Pharmacological Concepts of Temperament in Iranian Traditional Medicine

325

Pharmacological control of bleeding during cardiac surgery

326

Pharmacological control of periodontal disease. II. Antimicrobial agents

327

Pharmacological conversion of recent atrial fibrillation: a randomized, placebo-controlled study of three antiarrhythmic drugs

328

Pharmacological Correction of Early Embryogenesis Disorders in Cows

329

Pharmacological Differences of Glitazones: Does Peroxisome Proliferator-Activated Receptor-α Activation Make the Difference?

330

Pharmacological dissociation of autonomic and behavioural responses to fear in the medullary raphe

331

Pharmacological Effect of Caffeine on Drosophila melanogaster: A Proof-of-Concept in vivo Study for Nootropic Investigation

332

Pharmacological effects of a synthetic quinoline, a hybrid of tomoxiprole and naproxen, against acute pain and inflammation in mice: a behavioral and docking study

333

Pharmacological effects of biotin

334

Pharmacological effects of gallic acid in health and diseases: A mechanistic review

335

Pharmacological effects of low- dose of aspirin on Corpus Luteum functions in mature cycling female mice

336

Pharmacological effects of low- dose of aspirin on ovulation rate in mature cycling female mice

337

Pharmacological Effects of Origanum Vulgare L. in the Elevated Plus-Maze and Open Field Test in the Rat

338

Pharmacological Effects of Peganum harmala Seeds Extract on Isolated Rat Uterus

339

Pharmacological Effects of Rosa Damascena

340

Pharmacological effects of Safranal: An updated review

341

Pharmacological effects of tiludronate in horses after long-term immobilization

342

Pharmacological Effects on Brain Morphology and Cognitive Functions in Idiopathic Generalized Epilepsy

343

Pharmacological enhancement of cutaneous flap survival with topical dimethyl sulphoxide and hydrogen peroxide

344

Pharmacological Evaluation and Synthesis ofNewSulfonamides Derivatives Based on 1,4-Benzodioxane

345

Pharmacological evaluation of [11c]donepezil as tracer for visualization of acetylcholinesterase by PET

346

Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic?

347

Pharmacological evaluation of anti-inflammatory, antipyretic, analgesic, and antioxidant activities of Castanopsis costata leaf fractions (water, ethyl acetate, and n-hexane fractions): the potential medicinal plants from North Sumatra, Indonesia

348

Pharmacological evaluation of combined PGI2 agonists/thromboxane synthase inhibitors. I

349

Pharmacological Evaluation of Covid 19 Vaccine in Acute and Chronic Inflammatory Neuropathies

350

Pharmacological Evaluation of Ng5 and Ng5* Newly Synthesized Derivates of Heteroaryl-Amino-Ethanols

351

Pharmacological Evaluation of Oral Hypoglycemic and Antidiabetic Effects of Fresh Leaves Ethanol Extract of Morinda Lucida Benth. in Normal and Alloxan-Induced Diabetic Rats

352

Pharmacological Evaluation of Sedative activity of methanolic extract of Thuja occidentalis in mice.

353

Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential

354

Pharmacological Evaluation of Selected Medicinal Plants Used in the Management of Oral and Skin Infections in Ebem-Ohafia District, Abia State, Nigeria

355

Pharmacological evaluation of tea polysaccharides with antioxidant activity in gastric cancer mice

356

Pharmacological evaluation of the semi-purified fractions from the soft coral Eunicella singularis and isolation of pure compounds

357

Pharmacological evaluation of UK-14,304 analogs at cloned human α adrenergic receptors

358

Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues

359

Pharmacological evidence for curcumin neuroprotective effects against lead-stimulated neurodegeneration: possible role of Akt/GSK3 signaling pathway

360

Pharmacological evidence for lithium-induced neuroprotection against methamphetamine-induced neurodegeneration via Akt- 1/GSK3 and CREB-BDNF signaling pathways

361

Pharmacological evidence for activation of phospholipid and small GTP binding protein signalling cascades by Nod factors

362

Pharmacological Evidence That Multiple Phospholipid Signaling Pathways Link Rhizobium Nodulation Factor Perception in Medicago truncatula Root Hairs to Intracellular Responses, Including Ca^2+ Spiking and Specific ENOD Gene Expression

363

Pharmacological Evidences for the Antiamnesic Effects of Desmodium gangeticum in mice

364

Pharmacological evidences for the extracts and secondary metabolites from plants of the genus Hibiscus

365

Pharmacological Hypotension as a Cause of Delirious Mania ina Patient with Bipolar Disorder

366

Pharmacological implications of lengthened in-utero exposure to nevirapine Original Research Article

367

Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression

368

Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein

369

Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein

370

Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas

371

Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity Original Research Article

372

Pharmacological inhibition of DNA repair enzymes differentially modulates telomerase activity and apoptosis in two human leukaemia cell lines

373

Pharmacological inhibition of epsilon PKC suppresses chronic inflammation in murine cardiac transplantation model

374

Pharmacological inhibition of RhoA signaling prevents connective tissue growth factor induction in endothelial cells exposed to non-uniform shear stress

375

Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro

376

Pharmacological intervention of traditional Chinese medicine for the quality of life in patients with colorectal cancer: a systematic review and metaanalysis

377

PHARMACOLOGICAL INTERVENTIONS FOR GERIATRIC CACHEXIA: A NARRATIVE REVIEW OF THE LITERATURE

378

Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?

379

PHARMACOLOGICAL INVESTIGATION OF CASSIA SOPHERA, LINN. VAR. PURPUREA, ROXB

380

Pharmacological management of interferon-induced psychiatric disorders

381

Pharmacological management of metabolic syndrome and its lipid complications

382

Pharmacological management of mild or moderate persistent asthma

383

Pharmacological Management of Neuropathic Pain: Current Trends and Possible Approaches

384

Pharmacological management of tics in patients with TS

385

Pharmacological modulation of b-adrenoceptors as a new cardioprotective strategy for therapy of myocardial dysfunction induced by ischemia and reperfusion

386

Pharmacological modulation of the hyperpolarization-activated current (If) in human atrial myocytes: focus on G protein-coupled receptors

387

Pharmacological modulation of wound healing in experimental burns

388

Pharmacological outcomes in newly diagnosed epilepsy

389

Pharmacological outcomes in older people with newly diagnosed epilepsy

390

Pharmacological outcomes in people with mental retardation and epilepsy

391

PHARMACOLOGICAL PAIN RELIEF IN PEDIATRIC PATIENTS

392

Pharmacological postconditioning with the phytoestrogen genistein

393

Pharmacological potential of ferulic acid for the treatment of metabolic syndrome and its mechanism of action: Review

394

Pharmacological Potential of Some Indonesian Medicinal Plants as Promising Options for COVID-19 During the Pandemic Era: A Literature Review

395

Pharmacological preconditioning ameliorates neurological injury in a model of spinal cord ischemia

396

Pharmacological preconditioning of ischemic heart disease by low-dose dipyridamole

397

Pharmacological preconditioning with angiotensin converting enzyme inhibitors

398

Pharmacological preconditioning with angiotensin converting enzyme inhibitors; infarct size study

399

PHARMACOLOGICAL PRECONDITIONING WITH L-CARNITINE: RELEVANCE TO MYOCARDIAL HEMODYNAMIC FUNCTION AND GLYCOGEN AND LACTATE CONTENT

400

Pharmacological preconditioning with the adenosine triphosphate–sensitive potassium channel opener pinacidil

401

Pharmacological prevention of breast cancer: Quo vadis?

402

Pharmacological prevention of breast cancer: Quo Vadis?

403

Pharmacological prevention of prematurity

404

Pharmacological prevention of suicide in bipolar patients — A realizable target

405

Pharmacological Profile for the Contribution of NO/cGMP Pathway on Chlorpheniramine Antidepressant-Like Effect in Mice Forced Swim Test

406

Pharmacological profile of a nitric oxide donor spermine NONOate in the mouse corpus cavernosum

407

Pharmacological Profile of Oxazine and its Derivatives: A Mini Review

408

PHARMACOLOGICAL PROFILE OF SALVADORA PERSICA

409

Pharmacological profile of survivors of acute myocardial infarction at Turkish academic hospitals

410

Pharmacological Properties of Combination Therapies for Hypertension

411

Pharmacological properties of endothelins and big endothelins in ketamine/xylazine or urethane anesthetized rats

412

Pharmacological properties of fucose. Applications in age-related modifications of connective tissues

413

Pharmacological properties of serotonin receptor subtypes mediating contraction of bovine inferior alveolar arteries

414

Pharmacological properties of some 3-substituted indole derivatives, a concise overview

415

Pharmacological properties of some 3-substituted indole derivatives, a concise overview

416

Pharmacological Properties of Vochysia Haenkeana (Vochysiaceae) Extract to Neutralize the Neuromuscular Blockade Induced by Bothropstoxin-I (Lys49 Phospholipase A2) Myotoxin

417

Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study

418

Pharmacological regulation of cholesterol efflux in human monocyte-derived macrophages in the absence of exogenous cholesterol acceptors

419

Pharmacological Rescue of p53 in Cancer Therapy: Widening the Sensitive Tumor Spectrum by Targeting MDMX

420

Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress

421

Pharmacological research in pediatrics: From neonates to adolescents

422

Pharmacological salvage of a combined distal bypass and free flap with catheter-directed thrombolysis

423

Pharmacological Screening of Annona Muricata: A Review

424

Pharmacological spinal cord protection with magnesium during replacement of the thoracic and thoracoabdominal aorta

425

Pharmacological strategies for blood loss

426

Pharmacological strategies for blood loss

427

Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints

428

Pharmacological stress agents for evaluation of ischemic heart disease

429

Pharmacological Studies on Khamira Marwarid: Effect on Pentylenetetrazole-Induced Seizures, Cognition and Biochemical Markers in Mice

430

Pharmacological Studies on Tetracycline and Tetracycline Nanoemulsion Formulas

431

Pharmacological study of signal transduction during stimulation of prothoracic glands from Manduca sexta

432

Pharmacological Study of the Antitumor Effect of Newcastle Oncolytic Virus in Combination with Copper Nanoparticles, Hyperthermia and Radiation on Malignant Colorectal Cancer Cell Line

433

Pharmacological therapies in fibromyalgia

434

Pharmacological therapy of osteoarthritis

435

Pharmacological therapy of Pagetʹs and other metabolic bone diseases

436

Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature

437

Pharmacological treatment

438

Pharmacological treatment effects on eye movement control

439

Pharmacological Treatment in Behavioural Medicine

440

Pharmacological Treatment in Behavioural Medicine: The Importance of Neurochemistry, Molecular Biology and Mechanistic Hypotheses

441

Pharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else?

442

Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004

443

Pharmacological treatment of atrial fibrillation: a review on prevention of recurrences and control of ventricular response

444

Pharmacological treatment of chronic constipation: a literature review

445

Pharmacological treatment of established rheumatoid arthritis

446

Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain

447

Pharmacological treatment of hepatorenal syndrome: A note of optimism

448

Pharmacological treatment of multi-organ bodily distress syndrome: A double-blind, placebo-controlled trial of the effects of imipramine (stress-3)

449

Pharmacological treatment of portal hypertension: present and future

450

Pharmacological treatment of systolic heart failure

451

Pharmacological treatment of systolic heart failure

452

PHARMACOLOGICAL TREATMENT, LIFESTYLE MODIFICATION an‎d AWARENESS IN CORONARY ARTERY an‎d CEREBROVASCULAR DISEASE PATIENTS

453

PHARMACOLOGICAL TREATMENT, LIFESTYLE MODIFICATION AND AWARENESS IN CORONARY ARTERY AND CEREBROVASCULAR DISEASE PATIENTS

454

Pharmacological washout for the correct evaluation of the head-up tilt testing

455

Pharmacologically active microcarriers releasing glial cell line – derived neurotrophic factor: Survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats

456

Pharmacologically active microcarriers: a tool for cell therapy

457

Pharmacologically induced preconditioning with diazoxide: a novel approach to brain protection

458

Pharmacologically Relevant Drug Interactions of Nitrovasodilators

459

Pharmacologically relevant drug interactions of sulfonylurea antidiabetics with common herbs

460

Pharmacologically relevant drug interactions of sulfonylurea antidiabetics with common herbs

461

Pharmacologically tunable polyethylene-glycol-based cell growth substrate

462

Pharmacology – Prep Manual for Undergraduates

463

Pharmacology and clinical efficacy of angiotensin receptor blockers

464

Pharmacology and controlled release of hirudin for cardiovascular disorders

465

Pharmacology and Drug Interaction Effects of the Phosphodiesterase 5 Inhibitors: Focus on α-Blocker Interactions

466

Pharmacology and efficacy of cyclooxygenase (COX) inhibitors

467

Pharmacology and immunology of botulinum toxin type A

468

Pharmacology and medicines management for nurses (third edition),: George Downie, Jean Mackenzie and Arthur Williams (editors)Edinburgh, Churchill Livingstone, 2003, ISBN 0443071764, Pages 600, Price £22.99

469

Pharmacology and metabolism of alcohol, including its metabolic effects and interactions with other drugs

470

Pharmacology and phytochemistry studies in Peltophorum africanum

471

Pharmacology and Therapeutics: Principles to Practice

472

Pharmacology and Toxicology of Ethinyl Estradiol and Norethindrone Acetate in Experimental Animals

473

Pharmacology and Toxicology of Leflunomide

474

Pharmacology education: a theoretical framework of applied pharmacology and therapeutics

475

Pharmacology for midwives. The evidence base for safe practice: Sue Jordan; Palgrave Macmillan, Hampshire, UK, 512pp., price £20.99 paperback, ISBN 0333693965

476

Pharmacology of antiepileptic drugs during pregnancy and lactation

477

Pharmacology of Borage (Borago officinalis L.) Medicinal Plant

478

Pharmacology of carbon nanotubes: Toxicokinetics, excretion and tissue accumulation

479

Pharmacology of carvedilol

480

Pharmacology of coronary artery bypass grafts

481

Pharmacology of drugs used in neuroanaesthesia

482

Pharmacology of eprosartan, an angiotensin II receptor antagonist: Exploring hypotheses from clinical data, ,

483

Pharmacology of Free Radicals and the Impact of Reactive Oxygen Species on the Testis

484

Pharmacology of local anaesthesia in different age groups

485

Pharmacology of modern volatile anaesthetics

486

Pharmacology of New Agents for Acute Heart Failure Syndromes

487

Pharmacology of new aromatase inhibitors

488

Pharmacology of nitrous oxide

489

Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy

490

Pharmacology of serotonin-induced salivary secretion in Periplaneta americana

491

Pharmacology of skin aging. Stimulation of glycosaminoglycan biosynthesis by L-fucose and fucose-rich polysaccharides, effect of in vitro aging of fibroblasts

492

Pharmacology of systemic analgesics

493

Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells

494

Pharmacology of the fluoroquinolones: A perspective for the use in domestic animals

495

Pharmacology of the human red cell voltage-dependent cation channel. Part II: inactivation and blocking

496

Pharmacology of the human red cell voltage-dependent cation channel: Part I. Activation by clotrimazole and analogues

497

Pharmacology of the low-molecular-weight heparins, ,

498

Pharmacology of vascular smooth muscle: C.J. Garland and J.A. Angus (Editors) Oxford University Press, Oxford, UK, 1996; stg£65.00; 435 pp.; ISBN 0-19-262387-7

499

Pharmacology Teaching Methods and Affective Factors in Their Success in Educating Undergraduate Medical Students: A Scoping Review

500

Pharmacology, taxonomy and phytochemistry of the genus Artemisia specifically from Pakistan: a comprehensive review

501

Pharmacomechanical Thrombolytic Treatment in Symptomatic Acute and Subacute Deep Vein Thrombosis

502

Pharmacomodulation on the 3-acetylursolic acid skeleton: Design, synthesis, and biological evaluation of novel N-{3-[4-(3-aminopropyl)piperazinyl]propyl}-3-O-acetylursolamide derivatives as antimalarial agents Original Research Article

503

Pharmacophagous feeding stimulant activity of neo-clerodane diterpenoids for the turnip sawfly, Athalia rosae ruficornis

504

Pharmacophore and QSAR Modeling of Endothelial Nitric Oxide Synthase Inhibitors and Subsequent Validation and In Silico Search for New Hits

505

Pharmacophore and structure–activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase Original Research Article

506

Pharmacophore Based Virtual Screening Approach to Identify Selective PDE4B Inhibitors

507

Pharmacophore identification and 3D-QSAR studies in N-(2-benzoyl phenyl)-l-tyrosines as PPARγ agonists Original Research Article

508

Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr5,12, Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection Original Research Article

509

Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes

510

Pharmacophore identification of KSP inhibitors

511

Pharmacophore identification of Raf-1 kinase inhibitors

512

Pharmacophore identification of α1A-adrenoceptor antagonists

513

Pharmacophore interactions analysis and prediction of inhibitory activity of 1,7-diazacarbazoles as checkpoint kinase 1 inhibitors: application of molecular docking, 3D-QSAR and RBF neural network

514

Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors

515

Pharmacophore mapping studies on indolizine derivatives as 15-LOX inhibitors

516

Pharmacophore mapping studies on pyrazoles as anti-proliferative agents

517

Pharmacophore mapping: Prediction of BCR–ABL kinase inhibitory activity of α-benzylthio chalcones

518

Pharmacophore modeling and atom-based 3D-QSAR studies on amino derivatives of indole as potent isoprenylcysteine carboxyl methyltransferase (Icmt) inhibitors

519

Pharmacophore modeling and in silico screening for new KDR kinase inhibitors

520

Pharmacophore modeling and molecular dynamics simulation to identify the critical chemical features against human sirtuin 2 inhibitors

521

Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors

522

Pharmacophore modeling of cytochromes P450

523

Pharmacophore modeling, resistant mutant isolation, docking, and MM-PBSA analysis: Combined experimental/computer-assisted approaches to identify new inhibitors of the bovine viral diarrhea virus (BVDV) Original Research Article

524

Pharmacophore Modeling, Virtual Screening, Molecular Docking, DFT, and ADMET Analyses to Develop Newer generation Dual Orexin Receptor Antagonist Targeting Insomnia

525

Pharmacophore-based design, synthesis, biological evaluation, and 3D-QSAR studies of aryl-piperazines as α1-adrenoceptor antagonists

526

Pharmacophore-based discovery of 3,4-disubstituted pyrrolidines as a novel class of monoamine transporter inhibitors

527

Pharmacophore-based discovery of ligands for drug transporters

528

Pharmacophore-Based discovery of substituted pyridines as novel dopamine transporter inhibitors

529

Pharmacophore-Based discovery, synthesis, and biological evaluation of 4-phenyl-1-arylalkyl piperidines as dopamine transporter inhibitors

530

Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel

531

Pharmacophore-based virtual screening: The discovery of novel methionyl-tRNA synthetase inhibitors

532

Pharmacophoric features and Ca2+ ion holding capacity of verapamil

533

Pharmacophoric features of nucleosidic HIV-1RT inhibitors Original Research Article

534

Pharmacophoric features of Pseudomonas aeruginosa deacetylase LpxC inhibitors: An electronic and structural analysis

535

Pharmacophotonics: Utilizing multi-photon microscopy to quantify drug delivery and intracellular trafficking in the kidney

536

Pharmacopoeia of culture media — additional monographs (IV)

537

Pharmacopoeia of culture media—additional monographs (III)

538

Pharmacopoeial quality of drugs supplied by Nigerian pharmacies

539

Pharmacopuncture Versus Acepromazine in Stress Responses of Horses During Road Transport

540

Pharmaco-redox regulation of cytokine-related pathways: from receptor signaling to pharmacogenomics

541

Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis

542

Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009

543

Pharmacotherapy and evolution

544

Pharmacotherapy and smoking cessation at a tobacco dependence clinic

545

Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development

546

Pharmacotherapy Considerations in CKD Patients With COVID-19, A Narrative Review

547

Pharmacotherapy for obesity

548

Pharmacotherapy for pre diabetes: moving ahead

549

Pharmacotherapy for pregnant women with addictions

550

Pharmacotherapy for Reducing the Grieving Process of Romantic Relationship Breakup: A Clinical Trial

551

Pharmacotherapy for regional musculoskeletal pain

552

Pharmacotherapy for Retinoblastoma

553

Pharmacotherapy for severe aggression in a child with autism: “open label” evaluation of multiple medications on response frequency and intensity of behavioral intervention

554

Pharmacotherapy in acute coronary syndromes and acute myocardial infarction

555

Pharmacotherapy In Cardiopulmonary Resuscitation (CPR)

556

Pharmacotherapy in Endocrinology: Diabetes, Obesity, and Hy-perlipidemia- Review Article

557

Pharmacotherapy in percutaneous coronary intervention

558

Pharmacotherapy in the extreme longevity

559

Pharmacotherapy of bulimia nervosa and binge eating disorder

560

Pharmacotherapy of COVID-19: Considerations for Pregnancy and Breastfeeding

561

Pharmacotherapy of Depressed Children and Adolescents: Current Issues and Potential Directions

562

Pharmacotherapy of first-episode schizophrenia

563

Pharmacotherapy of impulsive aggression: A quality comparison of controlled studies

564

Pharmacotherapy of inflammatory process by ginger extract (Zingiber officinale) ointment

565

Pharmacotherapy of obesity

566

Pharmacotherapy of obesity

567

Pharmacotherapy of Prograf (Tacrolimus) in Liver Transplant Recipients; Consideration of Itsי Levels with Efficacy and Toxicity

568

Pharmacotherapy of schizophrenia

569

Pharmacotherapy of schizophrenia

570

Pharmacotherapy of schizophrenia

571

Pharmacotherapy of Schizophrenia: Ploypharmacy Approaches

572

Pharmacotherapy of social anxiety disorder

573

Pharmacotherapy of somatoform disorders

574

Pharmacotherapy or Psychotherapy? Selective Treatment Depression in The Infertile Women with Recurrent Pregnancy Loss: A Triple-Arm Randomized Controlled Trial

575

Pharmacotherapy Plays Main Role in Managing Acute Epiploic Appendagitis: A Case Report

576

Pharmacotherapy to Improve the Acquired Aphasia following Brain Damages: A Review Study

577

Pharmacotherapy Updates of Recombinant Tissue Plasminogen Activator (r-TPA) in Acute Ischemic Stroke

578

Pharmaco-toxicological study of diterpenoids Original Research Article

579

Pharmacovigilance Analysis of Serious Adverse Events Reported for Biologic Response Modifiers Used as Prophylaxis against Transplant Rejection: a Real-World Postmarketing Experience from the US FDA Adverse Event Reporting System (FAERS)

580

Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis

581

Pharmacovigilance in India, Uganda and South Africa with Reference to WHO’s Minimum Requirements

582

Pharmacovigilance in Qatar: a survey of pharmacists

583

Pharmacovigilance into 2000

584

PHARMACOVIGILANCE, 2nd Edition. R. Mann and E. Andrews, editors. Chichester:John Wiley & Sons; 2007.

585

Pharmacy and herbal medicine in the US

586

Pharmacy and Pharmacology Research in the BRICS Countries: A Scientometric Analysis

587

Pharmacy and the US Health Care System

588

Pharmacy approach to a case of acute diarrhoea with dehydration in Antalya, Turkey

589

Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions

590

Pharmacy education instruction: Preference and practices, Saudi students’ perception

591

Pharmacy impact on medication reconciliation in the medical intensive care unit

592

Pharmacy information systems in Tehran university hospitals and their relationship with pharmaceutical companies

593

Pharmacy madness

594

Pharmacy or PharmaNBIC: Thinking about 50 years ahead of pharmacy today

595

Pharmacy practice research: challenges and opportunities

596

Pharmacy practice, 3rd edition: Patricia Stone, Stephen J Curtis; Pharmaceutical Press, London, August 2002, 344pp, price £29.95 paperback, ISBN 0 85369 482 6,

597

Pharmacy Students Motivation, Preparation and Factors Affecting Pursuing Postgraduate Education in Ethiopian University

598

Pharmacy Studentsʹʹ Self-Identified Interests in a Hospital Pharmacy Internship Course in Iran

599

Pharmacy Students’ Satisfaction Rate with their Majors and its Relationship with Educational Status in Kermanshah University of Medical Sciences (2014)

600

Pharmacy Students’ Satisfaction Rate with their Majors and its Relationship with Educational Status in Kermanshah University of Medical Sciences (2014)

601

PHARMACY TOXICOLOGICAL ANALYSES FOR POISONED PATIENTS AT A TEACHING HOSPITAL IN SAUDI ARABIA

602

Pharmacyʹs attempts to extend its roles: A case study in South Africa

603

Pharmaphilia and pharmaphobia

604

p-Harmonic functions with boundary data having jump discontinuities and Baernsteinʹs problem

605

PHARMSEARCH, the Pharmaceutical Patents database produced by INPI

606

PHAROS: A pluri-detector, high-resolution, analyser of radiometric properties of soil

607

PHAROS: A pluri-detector, high-resolution, analyser of radiometric properties of soil

608

PHAROS: a spectrometer-on-a-chip for digital radiology systems with spectral detection

609

PHAROS: a spectrometer-on-a-chip for digital radiology systems with spectral detection

610

PHA–rubber blends: Synthesis, characterization and biodegradation

611

Pharyngeal Airway: An Analysis Using 2D vs. 3D Images in Different Malocclusions

612

Pharyngeal Aspiration of Complete Upper Denture in 90-Year-Old Man; a Case Report

613

Pharyngeal dysphagia in postesophagectomy patients: correlation with deglutitive biomechanics

614

Pharyngeal Myiasis Caused by Sheep Botfly, Oestrus ovis (Diptera: Oestridae) Larva, Tabriz, East Azarbaijan Province, Iran: A Case Report

615

Pharyngeal Packing during Rhinoplasty: Advantages and Disadvantages

616

Pharyngeal pH measurements in patients with respiratory symptoms before and during proton pump inhibitor therapy

617

Pharyngeal sensation and gag reflex in healthy subjects

618

Pharyngeal thyroid: a case report

619

Pharyngitis followed by hypoxia and sepsis: Lemierre syndrome

620

Pharyngitis treatment by emergency physicians from 1995 to 2001: do our antibiotic choices conform to national guidelines?

621

Pharyngocolonic Anastomosis for Esophageal Reconstruction in Corrosive Esophageal Stricture

622

Pharyngo-Colostomy With Supraglottic Partial Laryngectomy in Caustic Oropharyngeal Stricture

623

Pharyngocutaneous Fistula after Laryngectomy: Incidence, Predisposing Factors, and Outcome

624

Pharyngocutaneous Fistula as a Rare Late Postoperative Complication Following Submandibulectomy: A Case Report

625

Pharyngo-enteral anastomosis for esophageal reconstruction in diffuse corrosive esophageal stricture

626

PHARYNGOESOPHAGEAL FOREIGN BODIES

627

Pharyngoesophageal pH monitoring

628

Pharyngolaryngeal Involvement by Varicella-Zoster Virus

629

Pharyngo-oesophageal Foreign Bodies: Implications for Health Care Services in Nigeria

630

Phase (Liquid/Solid) Dependence of the Normal Spectral Emissivity for Iron, Cobalt, and Nickel at Melting Points

631

Phase 1 Trial of Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Patients with Decompensated Liver Cirrhosis

632

Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate

633

Phase 2 study of the combination of merimepodib with peginterferon-α2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C

634

Phase accumulation model analysis of quantum well resonances formed in ultra-thin Ag, Au films on W(1 1 0)

635

Phase ac-sensitivity of oxidic and acetylacetonic gas sensors

636

PHASE ADVANCE AFTER ONE OR THREE SIMULATED DAWNS IN HUMANS

637

Phase Agility of Reflectarray Patch Element Using Nematic Liquid Crystal

638

PHASE ANALYSIS AND DENSIFICATION OF STEATITE-BASED CERAMICS

639

Phase analysis and dielectric properties of oxides obtained in the MgO–(1–x)Nb2O5–(x)Ta2O5 system

640

Phase analysis and focusing of synchrotron radiation

641

Phase analysis and focusing of synchrotron radiation

642

Phase analysis and microstructure evolution of a bone china body modified with scrap addition

643

Phase analysis and microwave dielectric properties of BaO–Nd2O3–5TiO2 composite ceramics using variable size TiO2 reagents

644

Phase analysis and microwave dielectric properties of LTCC TiO2 with glass system

645

Phase Analysis and Oxygen Storage Capacity of Ceria-Lanthana-Based TWC Promoters Prepared by Sol–Gel Routes

646

Phase analysis and wear behavior of in-situ spark plasma sintered Ti3SiC2

647

Phase analysis in delayed systems

648

Phase Analysis in the Solder Joint of Sn-Cu Solder/IMCs/Cu Substrate

649

Phase analysis of Cu(In1 − xGax)Se2 prepared by solvothermal method

650

Phase Analysis of Gated Myocardial Perfusion Single-Photon Emission Computed Tomography Compared With Tissue Doppler Imaging for the Assessment of Left Ventricular Dyssynchrony Original Research Article

651

Phase analysis of Gd5(SixGe1−x)4 alloys prepared from different purity Gd with x = 0.475 and 0.43 Original Research Article

652

Phase analysis of Gd5(SixGe1-x)4 alloys prepared from different purity Gd with x = 0.475 and 0.43

653

Phase analysis of Mg–La–Nd and Mg–La–Ce alloys

654

Phase analysis of superconducting polycrystalline MgB2

655

Phase analysis of surface layers irradiated with high-energy electron beam using Mِssbauer spectroscopy

656

Phase analysis of surface layers irradiated with high-energy electron beam using Mِssbauer spectroscopy

657

Phase analysis of TaN/Ta barrier layers in sub-micrometer trench structures for Cu interconnects

658

Phase and aggregation behaviour of alkylglycosides

659

Phase and aggregational studies of some inversely soluble aqueous formulations

660

Phase and amplitude control of optical bistability in the three-coupled quantum wells

661

Phase and amplitude of ecosystem carbon release and uptake potentials as derived from FLUXNET measurements

662

Phase and anti-phase synchronization of fractional order chaotic systems via active control

663

Phase and Correlation in `Randomʹ Seismic Fields and the Reconstruction of the Green Function

664

Phase and critical behavior in type III phase diagrams

665

Phase and electrical behaviour in the Bi14W1 − xLaxO24 − 3x/2 system

666

Phase and group synchronization in second-harmonic generation of ultrashort light pulses in one-dimensional photonic crystals

667

Phase and intensity control through diffractive optical elements in X-ray microscopy

668

Phase and microstructural evolution during the heat treatment of Sm–Ca–α-sialon ceramics

669

Phase and microstructural evolution of heat treated nanocrystalline powders in Al2O3-MgO binary system

670

Phase and microstructural evolution of Ir–Si binary alloys with fcc/silicide structure

671

Phase and microstructural evolution of yttrium-doped nanocrystalline alumina: A contribution of advanced microscopy techniques

672

Phase and microstructural stability of solution precursor plasma sprayed thermal barrier coatings

673

Phase and microstructural stability of solution precursor plasma sprayed thermal barrier coatings

674

Phase and microstructural stability of solution precursor plasma sprayed thermal barrier coatings

675

Phase and microstructure evolution during hydrothermal solidification of clay–quartz mixture with marble dust source of reactive lime

676

Phase and microstructure evolution during the synthesis of WC nanopowders via thermal processing of the precursor

677

Phase and microstructure evolution in precursor plasma-sprayed YIG coatings

678

Phase and microstructure formation and their influence on the strength of two types of glass-ceramics

679

Phase and microstructure of TbCu7-type SmFe melt-spun powders

680

Phase and microstructure of tungsten coating on C/C composite prepared by double-glow plasma

681

Phase and microstructure stabilities of LiAlO2 in molten Li/Na carbonate for molten carbonate fuel cells

682

Phase and morphological transformations of GaS single crystal surface by thermal treatment

683

Phase and morphology changes induced by acid treatment following alkaline reaction of mesoporous anatase: Effect of anions

684

Phase and morphology control of LTA/FAU zeolites by adding trace amounts of inorganic ions

685

Phase and morphology dependence on the annealing temperature of tin sulfides and oxides prepared by thermal decomposition of organotin precursors

686

Phase and morphology evolution of bismuth ferrites via hydrothermal reaction route

687

Phase and morphology evolution study of ball milled Mg–Co hydrogen storage alloys

688

Phase and morphology investigation of BaxSr1−xTiO3 (x = 0.6, 0.7 and 0.8) powders

689

Phase and morphology investigation of BaxSr1−xTiO3 (x = 0.6, 0.7 and 0.8) powders

690

Phase and orientational ordering of A–B–A tri-block co-polymers guest in a quenched host of low molecular weight rod molecules

691

Phase and reaction equilibria of acetic acid–1-pentanol–water– n-amyl acetate system at 760 mm Hg

692

Phase and reaction equilibria of the acetic acid-isopropanol-isopropyl acetate-water system at 760 mmHg

693

Phase and rheological behaviors of xanthan/amylose and xanthan/starch mixed systems

694

Phase and scaling properties of determinants arising in topological field theories

695

Phase and sedimentation behavior of oil (octane) dispersions in the presence of model mineral aggregates

696

Phase and shape controlling of MnS nanocrystals in the solvothermal process

697

Phase- and shape-controlled hydrothermal synthesis of CdS nanoparticles, and oriented attachment growth of its hierarchical architectures

698

Phase- and shape-controlled synthesis of cadmium hydroxyl chloride microstructures via an ammonia-assisted conversion of 1D CdQCl (Q=quinoline) complex microwires Original Research Article

699

Phase and size control of nanometer-size materials synthesized in supersonic jet expansions

700

Phase and size control of nanometer-size materials synthesized in supersonic jet expansions

701

Phase and size separations occurring during the injection of model pastes composed of β-tricalcium phosphate powder, glass beads and aqueous solutions

702

Phase and space resolved optical emission spectroscopic investigations of an inductively coupled RF plasma using an imaging acousto-optic spectrometer

703

Phase and spectral properties of optically injected semiconductor lasers

704

Phase and state transition effects on dielectric, mechanical, and thermal properties of polyols

705

Phase and structural behavior of SmAlO3–RAlO3 (R = Eu, Gd) systems

706

Phase and structural change of carbonized wood materials by hydrothermal treatment

707

Phase and structural changes of Nd12Fe82B6 alloy during mechanical milling in both an argon and a hydrogen atmosphere

708

Phase and structural characterization of Sr2Nb2O7 and SrNbO3 thin films grown via pulsed laser ablation in O2 or N2 atmospheres

709

Phase and Structural Modifications in Porous Silicon Under Pulse Heating

710

Phase and structural transformations in magnetorheological suspensions

711

Phase and structure transformations in the titanium interlayer during the nickel silicidation on Si(1 0 0) substrate

712

Phase and Surface Properties of Lipid Bilayers Containing Neoglycolipids

713

Phase and texture analysis of a hydride blister in a Zr–2.5%Nb tube by synchrotron X-ray diffraction Original Research Article

714

Phase and thermal stability of nanocrystalline hydroxyapatite prepared via microwave heating

715

Phase and valence transitions in Ba2LnSnxNb1−xO6−δ

716

Phase and valence transitions in Ba2LnSnxSb1−xO6−δ (Ln=Pr and Tb)

717

Phase and velocity distributions in vertically upward high-viscosity two-phase flow

718

Phase and viscosity behaviour of refrigerant–lubricant mixtures

719

Phase and volumetric behavior of binary systems containing carbon dioxide and lubricants for transcritical refrigeration cycles

720

Phase and volumetric behaviour of mixtures of carbon dioxide (R-744) and synthetic lubricant oils

721

Phase angle dependence of sand density observable in hyperspectral reflectance

722

Phase angle in the Cu/polyimide/alumina system

723

Phase angle in the Cu/polyimide/alumina system

724

Phase Angle Measurement in Healthy Human Subjects through Bio-Impedance Analysis

725

Phase angle spectrum analysis and body water

726

Phase approximation by logarithmic sampling of gain

727

Phase assemblages of (Ca,Mg)-α-sialon ceramics derived from an α-sialon powder prepared by SHS

728

Phase assembly and microstructure of CeO2-doped ZrO2 ceramics prepared by spark plasma sintering

729

Phase association of polycyclic aromatic hydrocarbons in the Minjiang River Estuary, China

730

Phase associations and lipid distributions in the seasonally ice-covered Arctic estuary of the Mackenzie Shelf

731

Phase associations and potential selective extraction methods for selected high-tech metals from ferromanganese nodules and crusts with siderophores

732

Phase associations of barium in marine sediments

733

Phase Asymptotic Semiflows, Poincaréʹs Condition, and the Existence of Stable Limit Cycles

734

Phase asynchrony between coronal index and sunspot numbers Original Research Article

735

Phase attraction in sensorimotor synchronization with auditory sequences: Effects of Tsingle and periodic distractors on synchronization accuracy.

736

Phase averaging of the coherent head-on beam–beam instability

737

Phase averaging of the coherent head-on beam–beam instability

738

Phase averaging of the precessing vortex core in a swirl burner under piloted and premixed combustion conditions

739

Phase balancing using mixed-integer programming [distribution feeders]

740

Phase balancing using simulated annealing

741

Phase barograms–phase diagrams of vapor pressure: Eutectoid phase formation in binary systems

742

Phase based feature detector consistent with human visual system characteristics

743

744

Phase behavior and a modified Kwei equation for ternary polymer blends containing stereoregular PMMA

745

Phase behavior and characterization of ionic liquids based microemulsions

746

Phase behavior and compressibility factor of two China gas condensate samples at pressures up to 95 MPa

747

Phase behavior and crystal structure of 3-(1-naphthyloxy)- and 3-(4-indolyloxy)-propane-1,2-diol, synthetic precursors of chiral drugs propranolol and pindolol

748

Phase Behavior and Crystal Structure of Perovskite-Type Rare Earth Complex Oxides

749

Phase behavior and crystallization in blends of a low molecular weight polyethylene-block-poly(ethylene oxide) diblock copolymer and poly(hydroxyether of bisphenol A)

750

Phase behavior and emulsion formation of novel fluoroether amphiphiles in carbon dioxide

751

Phase behavior and extraction characteristics of polycyclic aromatic hydrocarbon mixtures with hexane in sub- and supercritical state

752

Phase behavior and hydrogen bonding in biomembrane mimicing polyurethanes with long side chain fluorinated alkyl phosphatidylcholine polar head groups attached to hard block

753

Phase behavior and interfacial curvature in water-oil-surfactant systems

754

Phase behavior and its viscoelastic response of polylactide/poly(ε-caprolactone) blend

755

Phase behavior and kinetics of a new bond-order potential for silicon

756

Phase behavior and Lα-phase of a new catanionic system formed by cationic hydrocarbon and anionic fluorocarbon surfactants

757

Phase behavior and mechanism of membrane formation for polyimide/DMSO/water system

758

Phase behavior and mesoscale solubilization in aqueous solutions of hydrotropes

759

Phase behavior and microstructural length scales of a diblock copolymer in the presence of a selective solvent

760

Phase behavior and microstructure of preheated soy proteins and κ-carrageenan mixtures

761

Phase behavior and microstructures of the Gemini (12-3-12,2Br−)–SDS–H2O ternary

762

Phase behavior and miscibility in blends of poly(sebacic anhydride)/poly(ethylene glycol)

763

Phase behavior and mixed ionic–electronic conductivity of Ba4Sb2O9

764

Phase behavior and modeling of the poly(methyl methacrylate)–CO2–methyl methacrylate system

765

Phase behavior and modeling of the systems CO2-acetonitrile and CO2-acrylic acid

766

Phase behavior and molecular chain environment of organic–inorganic hybrid materials based on poly(n-butyl methacrylate-co-(3-(methacryloxypropyl)) trimethoxysilane)

767

Phase behavior and morphology of poly(phenylene ether)/epoxy blends

768

Phase behavior and optical- and mechanical properties of the binary system isotactic polypropylene and the nucleating/clarifying agent 1,2,3-trideoxy-4,6:5,7-bis-O-[(4-propylphenyl) methylene]-nonitol

769

Phase behavior and optical investigation of two synthetic luminol derivatives and glycolipid mixed monolayers at the air–water interface

770

Phase behavior and phase structure of 1:1 salt-free catanionic surfactant dodecyltrimethylammonium decanoate

771

Phase behavior and physical properties of petroleum reservoir fluids from acoustic measurements

772

Phase behavior and process parameters effects on the characteristics of precipitated theophylline using carbon dioxide as antisolvent

773

PHASE BEHAVIOR AND PROPERTIES OF POLYURETHANE-PVC BLENDS AND FIBERS

774

PHASE BEHAVIOR AND PROPERTIES OF POLYURETHANE-PVC BLENDS AND FIBERS

775

Phase behavior and protein partitioning in aqueous two-phase systems of cationic–anionic surfactant mixtures

776

Phase behavior and reaction of polyethylene in supercritical water at pressures up to 2.6 GPa and temperatures up to 670°C

777

Phase behavior and rheology in water and in model paint formulations thickened with HM-EHEC: influence of the chemical structure and the distribution of hydrophobic tails

778

Phase behavior and SANS investigations of edible sugar–limonene microemulsions

779

Phase behavior and size variation of AOT-based W/O microemulsions by substituting H+ for Na+ as the counterion

780

Phase behavior and size variation of Na-AOT-based W/O microemulsions by increasing NaOH concentration in the water pool

781

Phase behavior and spherical hollow particle formation by dipeptide-based two-headed amphiphiles in a mixed solvent of dimethyl sulfoxide and water

782

Phase behavior and structure formation for diblock copolymers composed of side-chain liquid crystalline and glassy amorphous components

783

Phase behavior and surface tensions of amphiphilic fluorinated random copolymer aqueous solutions

784

Phase behavior and thermodynamic properties in the system Fe–Al

785

Phase behavior and thermodynamic properties in the system Fe–Al

786

Phase behavior and vapor pressures of the pyrene + 9,10-dibromoanthracene system

787

Phase behavior and viscous properties of cetyltrimethylammonium bromide and sodium dodecyl sulfonate aqueous mixtures

788

Phase behavior and water vapor transport in BIONOLLE/polymethylmethacrylate blends

789

Phase behavior applications of SAFT based equations of state—from associating fluids to polydisperse, polar copolymers

790

Phase behavior at low temperature of poly(tetrafluoroethylene) by temperature-modulated calorimetry

791

Phase behavior for carbon dioxide + ethanol system: Experimental measurements and modeling with a cubic equation of state

792

Phase behavior for carbon dioxide/tetraalkoxysilane systems

793

Phase behavior for the [Bmim]BF4 aqueous two-phase systems containing ammonium sulfate/sodium carbonate salts at different temperatures: Experimental and correlation

794

Phase behavior for the poly(dimethylsiloxane) in supercritical fluid solvents

795

Phase behavior for the poly[2-(2-ethoxyethoxy)ethyl acrylate] and 2-(2-ethoxyethoxy)ethyl acrylate in supercritical solvents

796

Phase behavior for the supercritical ethylene + hexane + polyethylene systems

797

Phase behavior in liquid crystallization for diblock copolymers consisting of rubbery amorphous and side-chain liquid crystalline components

798

Phase behavior in mixtures of cationic surfactant and anionic polyelectrolytes

799

Phase behavior in the system LaxSr1-xMnO(5+x)/2 (x=0.8-1.0) with trivalent state of manganese ion

800

Phase behavior measurement for poly(isobornyl acrylate) + cosolvent systems in supercritical solvents at high pressure

801

Phase behavior measurement for the system CO2 + glycerol + ethanol at high pressures

802

Phase behavior measurement of the binary carbon dioxide–N,N-dimethylacetamide and carbon dioxide–N,N-diethylacetamide systems at high pressure

803

Phase behavior measurement on the binary mixture for isopropyl acrylate and isopropyl methacrylate in supercritical CO2

804

Phase behavior of (polyacrylamides + water) solutions: concentration, pressure and isotope effects

805

Phase behavior of 1,3,5-tri-tert-butylbenzene–carbon dioxide binary system

806

Phase behavior of a model surfactant–solvent system at intermediate and high densities

807

Phase behavior of a near-critical reservoir fluid mixture

808

Phase behavior of a nematic liquid crystal in polybutadiene networks

809

Phase behavior of a simple model of ferrocolloidal fluid

810

Phase behavior of a ternary system of poly[p-perfluorooctyl-ethylene(oxy, thio, sulfonyl)methyl styrene] and poly[p-decyl(oxy, thio, sulfonyl)methyl styrene] in supercritical solvents

811

Phase behavior of a two-dimensional quenched–annealed lattice gas with nearest-neighbor attraction. Grand canonical Monte Carlo simulation

812

Phase behavior of amphiphile–solvent systems from lattice Monte Carlo simulations

813

Phase behavior of an amphiphilic molecule in the presence of two solvents by dissipative particle dynamics

814

Phase behavior of aqueous two-phase systems composed of 1-alkyl-3-methylimidazolium bromide + Rb2CO3/Cs2CO3 + water

815

Phase behavior of aqueous two-phase systems composed of 1-ethyl-3-methylimidazolium tetrafluoroborate and phosphate-based salts at different temperatures

816

Phase behavior of Athabasca bitumen + water mixtures at high temperature and pressure

817

Phase behavior of banana-shaped molecules under pressure

818

Phase Behavior of Binary and Ternary Mixtures of Poly(decyl acrylate)-Supercritical Solvents-Decyl Acrylate and Poly(decyl methacrylate)-CO2-Decyl Methacrylate Systems

819

Phase behavior of binary mixture for the isoalkyl acetate in supercritical carbon dioxide

820

Phase behavior of binary mixture of asphaltene + solvent and ternary mixture of asphaltene + solvent + precipitant

821

Phase behavior of binary mixtures of thick and thin hard rods

822

Phase Behavior of Binary Stockmayer and Polarizable Lennard-Jones Fluid Mixtures Using Adiabatic Nuclear and Electronic Sampling

823

Phase behavior of biodegradable amphiphilic poly(l,l-lactide)-b-poly(ethylene glycol)-b-poly(l,l-lactide)

824

Phase behavior of blends of high temperature copolycarbonates with styrene/acrylonitrile copolymers

825

Phase behavior of blends of linear and branched polyethylenes on micron length scales via ultra-small angle neutron scattering (USANS)

826

Phase behavior of blends of linear low density polyethylene and poly(ethene-propene-1-butene)

827

Phase behavior of blends of poly(2,6-dimethyl-1,4-phenylene oxide)/polystyrene/poly(o-chlorostyrene-co-p-chlorostyrene) copolymer

828

PHASE BEHAVIOR OF BROMINATED POLY(ISOBUTYLENE-co-4-METHYLSTYRENE)/ GENERAL PURPOSE RUBBER BLENDS

829

PHASE BEHAVIOR OF BROMINATED POLY(ISOBUTYLENE-co-4-METHYLSTYRENE)/ GENERAL PURPOSE RUBBER BLENDS

830

Phase behavior of carbon dioxide mixtures with n-alkanes and n-perfluoroalkanes

831

Phase behavior of carbon dioxide + medroxyprogesterone acetate system at high pressures

832

Phase behavior of carbon dioxide—low-molecular weight triglycerides binary systems: measurements and thermodynamic modeling

833

Phase behavior of castor oil in compressed propane and n-butane

834

Phase behavior of catalytic deactivated compounds and water with 1-ethyl-3-methylimidazolium acetate [EMIM][OAc] ionic liquid at T = 298.15–323.15 K and p = 1 bar

835

Phase behavior of CO2 + polyethylene glycol + ethanol at pressures up to 20 MPa

836

Phase behavior of concentrated hydroxypropyl methylcellulose solution in the presence of mono and divalent salt

837

Phase behavior of crosslinked polyisoprene rubber and supercritical carbon dioxide

838

Phase behavior of didecylpyrrolidium bromide in aqueous solution

839

Phase behavior of diisobutyl adipate–carbon dioxide mixtures

840

Phase behavior of dipalmitoylphosphatidylethanolamine in dimethylsulfoxide–water mixture

841

Phase behavior of DNA in the presence of cetyltrimethylammonium bromide \ alkyl polyglucoside surfactant mixture

842

Phase behavior of DNA solutions in the presence of salts

843

Phase behavior of imidazolium and phosphonium tetrafluoroborates with dihydroxy alcohols

844

Phase Behavior of Ionic Liquid-LiX Mixtures: Pyrrolidinium Cations and TFSI- Anions

845

Phase behavior of iridescent phases with calcium dodecyl sulfate, octanol or decanol, and water, and the effect of the presence of sodium ions

846

Phase behavior of isotactic polypropylene/C4-solvents at high pressure. Experimental data and SAFT modeling

847

Phase behavior of lemon and bergamot peel oils in supercritical CO2

848

Phase behavior of Lennard-Jones fluids in pores formed between two cylindrical walls

849

Phase behavior of LiClO4-doped poly(ε-caprolactone)-b-poly(ethylene oxide) hybrids in the presence of competitive interactions

850

Phase behavior of linear polystyrene-block-poly(2-vinylpyridine)-block-poly(tert-butyl methacrylate) triblock terpolymers

851

Phase behavior of liquid-crystalline copolymer/liquid crystal blends

852

Phase behavior of magnetic nanoparticles dispersions in bulk and confined geometries

853

Phase behavior of metals at very high P–T conditions: A review of recent experimental studies Original Research Article

854

Phase behavior of methane and carbon dioxide hydrates in meso- and macro-sized porous media

855

Phase behavior of microemulsions based on food-grade nonionic surfactants: effect of polyols and short-chain alcohols

856

Phase behavior of mixtures of ionic liquids and organic solvents

857

Phase behavior of n-hexadecyl phosphate in Gibbs adsorption layers

858

Phase behavior of ovalbumin and carboxymethylcellulose composite system

859

Phase behavior of phytosterols and cholesterol in carbon dioxide-expanded ethanol

860

Phase behavior of poly(1,1-dihydroperfluorooctylacrylate) in supercritical carbon dioxide

861

Phase behavior of poly(3-alkylthiophene)/polystyrene blends

862

Phase behavior of poly(dimethylsiloxane)–poly(ethylene oxide) amphiphilic block and graft copolymers in compressed carbon dioxide

863

Phase behavior of poly(ether imide) in mixtures of N-methyl-2-pyrrolidinone and methylene chloride

864

Phase behavior of poly(N-isopropylacrylamide) in binary aqueous solutions

865

Phase behavior of poly(N-isopropylacrylamide) in water–methanol cononsolvent mixtures and its relevance to membrane formation

866

Phase behavior of polyaniline/dodecyl benzene sulphonic acid mixture

867

Phase behavior of polyetherimide/benzophenone/triethylene glycol ternary system and its application for the preparation of microporous membranes

868

Phase behavior of polymer/diluent/diluent mixtures and their application to control microporous membrane structure

869

Phase behavior of polymer–diluent systems characterized by temperature modulated differential scanning calorimetry

870

Phase behavior of polymers containing ether groups in carbon dioxide

871

Phase behavior of polymer–solvent mixtures

872

Phase behavior of polypropylene + n-pentane and polypropylene + n-pentane + carbon dioxide: modeling with cubic and non-cubic equations of state

873

Phase behavior of propane and n-pentane aerosol particles under conditions relevant to Titan

874

Phase behavior of random and ABC triblock methacrylic polyampholytes with poly(vinyl alcohol) in water: effect of pH and salt

875

Phase behavior of reservoir fluids: Comparisons of PC-SAFT and cubic EOS simulations

876

Phase Behavior of Rigid Objects on a Cubic Lattice

877

Phase behavior of Safaniya vacuum residue

878

Phase behavior of selected artificial lipids

879

Phase behavior of semicrystalline polymer blends

880

Phase behavior of serpentine mineral by carbothermal reduction nitridation

881

Phase Behavior of Sick House Syndrome(SHS) Chemicals

882

Phase behavior of siloxane-based amphiphiles in supercritical carbon dioxide

883

Phase behavior of some mono-substituted ferrocene- and [3]ferrocenophane-containing nematics with the cyclohexane ring in the rigid core

884

Phase behavior of sour natural gas systems using classical and statistical thermodynamic equations of states

885

Phase behavior of soybean oil, castor oil and their fatty acid ethyl esters in carbon dioxide at high pressures

886

Phase behavior of sunflower oil and soybean oil in propane and sulphur hexafluoride

887

Phase behavior of supercritical CO2/Styrene/Poly(ethylene terephthlate) (PET) system and preparation of polystyrene/PET composites

888

Phase behavior of ternary mannosylerythritol lipid/water/oil systems

889

Phase Behavior of the Binary and Ternary Mixtures of Biodegradable Poly((epsilon)-caprolactone) in Supercritical Fluids

890

Phase behavior of the binary refrigerant mixture chlorodifluoro-ethane (R22)-1,1,1,2-tetrafluoro-ethane (R134a): experimental investigation and theoretical modelling using the perturbed-anisotropic-chain theory (PACT)

891

Phase behavior of the binary system ethane+linalool

892

Phase behavior of the binary system near-critical dimethylether and tripalmitin: measurements and thermodynamic modeling

893

Phase behavior of the monoolein–water system: The effects of addition of the hydrocarbon 1,8-cineole and supercritical carbon dioxide

894

Phase behavior of the orange essential oil/sodium bis(2-ethylhexyl)sulfosuccinate/water system

895

Phase behavior of the poly(neopentyl methacrylate) + supercritical fluid solvents + neopentyl methacrylate system and CO2 + neopentyl methacrylate mixtures at high pressure

896

Phase behavior of the poly(vinyl pyrrolidone) + N-vinyl-2-pyrrolidone + carbon dioxide system

897

Phase behavior of the poly(vinyl pyrrolidone) + dichloromethane + supercritical carbon dioxide system

898

Phase behavior of the system hyperbranched polyglycerol + methanol + carbon dioxide

899

Phase behavior of the system lecithin–water: The effects of addition of the hydrocarbon 1,8-cineole and supercritical carbon dioxide

900

Phase behavior of the ternary 1-hexyl-3-methylimidazolium tetrafluoroborate + carbon dioxide + methanol system

901

Phase behavior of the ternary aqueous mixtures of two polydisperse ethoxylated nonionic surfactants

902

Phase behavior of the vanillin–CO2 system at high pressures

903

Phase behavior of tri-block copolymers in solution: Mesoscopic simulation study

904

Phase behavior of tricyanomethanide-based ionic liquids with alcohols and hydrocarbons

905

Phase behavior of two-component membranes

906

Phase behavior of unsymmetrical dimers on a square lattice

907

Phase behavior of vinyl fluoride in room-temperature ionic liquids [emim][Tf2N], [bmim][N(CN)2], [bmpy][BF4], [bmim][HFPS] and [omim][TFES]

908

Phase behavior of water + hydrocarbon binary systems by using multi-fluid nonrandom lattice hydrogen bonding theory

909

Phase behavior of water-in-supercritical carbon dioxide microemulsion with sodium salt of bis(2,2,3,3,4,4,5,5-octafluoro-1-pentanol) sulfosuccinate

910

Phase behavior of xenon hydrate system

911

Phase behavior of β-d galactose pentaacetate–carbon dioxide binary system

912

Phase behavior on the poly[octyl (meth)acrylate] + supercritical fluid solvents + monomer and CO2 + monomer mixtures at high pressure

913

Phase behavior prediction of complex petroleum fluids

914

Phase behavior prediction of petroleum fluids with minimum characterization data

915

Phase behavior studies of a perfluoropolyether in high-pressure carbon dioxide

916

Phase behavior studies of a perfluoropolyether in high-pressure carbon dioxide

917

Phase behavior study of amphiphilic drugs: Effect of pharmaceutical excipients

918

Phase behavior study of paclitaxel loaded amphiphilic copolymer in two solvents by dissipative particle dynamics simulations

919

Phase behavior study of PEB/PES blend by time resolved laser light scattering

920

Phase behavior, formation, and rheology of cubic and hexagonal phase based gel emulsions in water/tetraglyceryl lauryl ether/oil systems

921

Phase behavior, microstructure transition, and antiradical activity of sucrose laurate/propylene glycol/the essential oil of Melaleuca alternifolia/water microemulsions

922

Phase behavior, morphology and interfacial structure in thermoset/thermoplastic elastomer blends of poly(propylene glycol)-type epoxy resin and polystyrene–b-polybutadiene

923

Phase behavior, nucleation and optical properties of the binary system isotactic polypropylene/N,N′,N″-tris-isopentyl-1,3,5-benzene-tricarboxamide

924

Phase behavior, ordering and self-assembly in monolayers

925

Phase behavior, photopolymerization, and morphology development in mixtures of eutectic nematic liquid crystal and photocurable monomer

926

Phase behavior, polymorphism and spherulite morphology in Poly(1,4-butylene adipate) interacting with two structurally similar acrylic polymers

927

Phase Behavior, Thermal Stability and Rheological Properties of PPEK/PC Blends

928

Phase behaviors and light scattering for dilute mixtures of C12E5 and lauric acid

929

Phase behaviors for the supercritical ethylene + 1-hexene + hexane + polyethylene systems at elevated temperatures and pressures

930

Phase behaviors of ammonia/R-125 mixtures

931

Phase behaviors of bidisperse nanoparticle/block copolymer mixtures in dilute solutions

932

Phase Behaviors of Binary Hard-Sphere Mixtures Using Simple Analytical Equations of State

933

Phase behaviors of comb-like liquid crystalline polysiloxanes containing fluorinated mesogenic units

934

Phase behaviors of Gemini cationic surfactants/n-butanol/water systems

935

Phase behaviors of polymer solution confined between two concentric cylinders

936

Phase behaviors of smectic-A liquid crystal/linear polymer systems Original Research Article

937

Phase behaviors of solid polymer electrolyte/salt systems in lithium secondary battery: the ionic interaction and nonrandomness effect

938

Phase behaviors of solid polymer electrolytes/salt system in lithium secondary battery by group-contribution method: The pressure effect

939

Phase behaviors of sphere-forming triblock copolymers confined in nanopores: A dynamic density functional theory study

940

Phase behaviour and density of (methane+n-butane)

941

Phase behaviour and density of model reservoir fluids at high temperature and pressure

942

Phase behaviour and in vitro hydrolysis of wheat starch in mixture with whey protein

943

Phase behaviour and miscibility window in UCST-type blends of poly(styrene-co-acrylonitrile) and tetramethylbisphenol A oligosulfones

944

Phase behaviour and non-periodic crystallisation of random aromatic copolyesters and their side chain bearing systems

945

Phase behaviour and physico-chemical properties of the binary systems {1-ethyl-3-methylimidazolium thiocyanate, or 1-ethyl-3-methylimidazolium tosylate + water, or + an alcohol}

946

Phase behaviour and thermodynamics of poly(1,4-phenylene ether sulphone) and poly(ethylene oxide)/alkali-metal salt complex blends: a thermal analysis study

947

Phase behaviour in the vicinity of the three-phase solid–liquid–vapour line in asymmetric nonpolar systems at high pressures

948

Phase behaviour of 1-butyl-1-methylpyrrolidinium thiocyanate ionic liquid

949

Phase behaviour of 1-hexyloxymethyl-3-methyl-imidazolium and 1,3-dihexyloxymethyl-imidazolium based ionic liquids with alcohols, water, ketones and hydrocarbons: The effect of cation and anion on solubility

950

Phase behaviour of 1-methyl-3-octylimidazolium bis[trifluoromethylsulfonyl]imide with thiophene and aliphatic hydrocarbons: The influence of n-alkane chain length

951

Phase behaviour of a liquid crystalline polyetherester derived from 4′-hydroxy-1,1′-biphenyl-4-carboxylic acid and the ether-diol 4-(3-hydroxypropoxy)butan-1-ol

952

Phase behaviour of a mixed ionic/nonionic surfactant system used to prepare stable oil-in-water paraffin emulsions

953

Phase behaviour of a non-ionic surfactant–polymeric solution–water system during the phase inversion process

954

Phase behaviour of binary fluid mixtures: a global phase diagram solely in terms of pure component properties

955

Phase behaviour of binary mixtures of colloidal charged spheres

956

Phase behaviour of binary mixtures of LC compounds of different molecular structure and comparable molecular length: I. 4-(4′-Substituted phenylazo)phenyl-4″-alkoxybenzoates and 4-(4′-substituted phenyl carbonyloxy)phenyl-4″-alkoxybenzoates

957

Phase behaviour of dipalmitoylphosphatidylcholine/surfactant/water systems studied by infrared spectroscopy

958

Phase behaviour of gas hydrates of carbon dioxide in the presence of tetrahydropyran, cyclobutanone, cyclohexane and methylcyclohexane

959

Phase behaviour of gelatin/polydextrose mixtures at high levels of solids

960

Phase behaviour of globular protein and flexible polymer in an aqueous medium

961

Phase behaviour of heteronuclear dimers adsorbed on square and triangular lattices—a Monte Carlo study

962

Phase behaviour of high molecular mass methyl esters in supercritical ethane

963

Phase behaviour of high molecular weight oat β-glucan/whey protein isolate binary mixtures

964

Phase behaviour of hyperbranched polyesters and polyethers with modified terminal OH groups in supercritical solvents

965

Phase behaviour of ionic liquid 1-butyl-1-methylpyrrolidinium tris(pentafluoroethyl)trifluorophosphate with alcohols, water and aromatic hydrocarbons

966

Phase behaviour of lipid–cholesterol membranes

967

Phase behaviour of l-lactic acid based polymers of low molecular weight in supercritical carbon dioxide at high pressures

968

Phase behaviour of l-lactide in supercritical carbon dioxide at high pressures

969

Phase behaviour of Maya crude oil based on calorimetry and rheometry

970

Phase behaviour of microemulsions stabilised by double chain cationic surfactants and alcohol co-surfactants

971

Phase behaviour of mixtures containing antibiotics: Effect of hydrogen bonding on tetracycline partitioning

972

Phase behaviour of oat β-glucan/sodium caseinate mixtures varying in molecular weight

973

Phase behaviour of oxygen adsorbed on graphite

974

Phase Behaviour of Palm Oil Fatty Acid Components in Supercritical Carbon Dioxide

975

Phase behaviour of polymer emulsions during the phase inversion process in the presence of non-ionic surfactants

976

Phase behaviour of pure micellar casein/κ-carrageenan systems in milk salt ultrafiltrate

977

Phase behaviour of RbH2AsO4 above room temperature

978

Phase behaviour of SMMA and SAN blends using Floryʹs equation of state theory

979

Phase behaviour of ternary system styrene–maleic anhydride (SMA) and two styrene–acrylonitrile (SAN) copolymers having different compositions

980

Phase behaviour of the binary mixtures of substituted analogues of LC compounds of the type 4-(4′-substituted phenylazo)-1-naphthyl-4″-alkoxybenzoates

981

Phase behaviour of the binary system ethane+limonene

982

Phase behaviour of the catalyst dicarbonyl(η5-cyclopentadienyl)-cobalt in carbon dioxide

983

Phase behaviour of water+nonionic surfactant systems: experiments and modelling applying the Peng–Robinson equation of state with the Wong–Sandler mixing rules and the UNIQUAC gE-model

984

Phase behaviour study of chalcone in dense CO2

985

Phase behaviour, rheological properties, and microstructure of oat β-glucan-milk mixtures

986

Phase behaviour, rheology and microstructure of mixture of meat proteins and kappa and iota carrageenans

987

Phase bifurcations of electron gas at the conditions of diamagnetic instability

988

Phase Boundaries and Crystallization of Polyethylene in n-Pentane and n-Pentane + Carbon Dioxide Fluid Mixtures

989

Phase boundaries as agents of structural change in macromolecules

990

Phase boundaries of the φ-Al10Cu10Fe1 phase

991

Phase boundary between ilmenite and perovskite structures in MnGeO3 determined by in situ X-ray diffraction measurements

992

Phase Boundary Estimation in Two-Phase Flows with Electrical Impedance Imaging Technique

993

Phase boundary migration, Kirkendall marker shift and atomic mobilities in fcc Au–Pt alloys

994

Phase boundary of dilute lattice spin glasses

995

Phase boundary of pressure-induced I4mm to Cmc21 transition in ammonia borane at elevated temperature determined using Raman spectroscopy

996

Phase boundary of the Zr-rich region in commercial grade Zr–Nb alloys

997

Phase boundary solutions to model kinetic equations via the Conley index theory. Part I

998

Phase boundary solutions to model kinetic equations via the Conley index theory. Part II

999

Phase breaks and chaos in a chain of diffusively coupled oscillators

1000

Phase Calibration Technique for Mismatch Optimization in Image-Reject Receivers

بازگشت